Roluperidone is primarily investigated for its application in the treatment of negative symptoms associated with schizophrenia. These symptoms include social withdrawal, reduced emotional expression, and lack of motivation, which are often challenging to manage with existing therapies. The compound functions as a serotonin 5-HT2A receptor antagonist and sigma-2 receptor modulator, targeting pathways implicated in the pathophysiology of these symptoms. Clinical trials have explored its efficacy in improving patients' functional outcomes and quality of life, particularly when used as an adjunct to antipsychotic medications. Its potential to address unmet needs in schizophrenia treatment makes it a promising candidate in psychiatric medicine.